Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “PTC THERAPEUTICS, INC.”

149 pharma patents match "PTC THERAPEUTICS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 149
Index total 30,257
Page 2 / 7

Quick answer

This filtered view shows 149 pharmaceutical patents matching "PTC THERAPEUTICS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

149 results for “PTC THERAPEUTICS, INC.” · 30,257 patents in full index Clear search

  1. US 11407753

    Compounds for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted
  2. US 11395822

    Methods for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Granted Jul 26, 2022 · Expires Jul 21, 2042

    granted
  3. US 11390588

    2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof

    PTC THERAPEUTICS, INC. · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  4. US 11382918

    Methods for treating Huntington's Disease

    PTC THERAPEUTICS, INC. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  5. US 11304914

    Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

    PTC THERAPEUTICS, INC. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted
  6. US 11180483

    Substituted reverse pyrimidine Bmi-1 inhibitors

    PTC THERAPEUTICS, INC. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted
  7. US 11174212

    2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders

    PTC THERAPEUTICS, INC. · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted
  8. US 11083737

    Methods of administering deflazacort therapy

    PTC THERAPEUTICS, INC. · Granted Aug 10, 2021 · Expires Aug 5, 2041

    granted
  9. US 11021424

    Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers

    PTC THERAPEUTICS, INC. · Granted Jun 1, 2021 · Expires May 27, 2041

    granted
  10. US 10981855

    Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

    PTC THERAPEUTICS, INC. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted
  11. US 10968166

    4-(P-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases

    PTC THERAPEUTICS, INC. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted
  12. US 10959988

    Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid for the treatment of disease

    PTC THERAPEUTICS, INC. · Granted Mar 30, 2021 · Expires Mar 25, 2041

    granted
  13. US 10898585

    Gene therapy for AADC deficiency

    PTC THERAPEUTICS, INC. · Granted Jan 26, 2021 · Expires Jan 21, 2041

    granted
  14. US 10881658

    Methods for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted
  15. US 10874672

    Methods for treating Huntington's disease

    PTC THERAPEUTICS, INC. · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted
  16. US 10851101

    Compounds for treating spinal muscular atrophy

    PTC THERAPEUTICS, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  17. US 10849885

    Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy

    PTC THERAPEUTICS, INC. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted
  18. US 10751302

    Polymorphic and amorphous forms of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide

    PTC THERAPEUTICS, INC. · Granted Aug 25, 2020 · Expires Aug 20, 2040

    granted
  19. US 10738014

    2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof

    PTC THERAPEUTICS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  20. US 10736857

    Treatment of pervasive developmental disorders with redox-active therapeutics

    PTC THERAPEUTICS, INC. · Granted Aug 11, 2020 · Expires Aug 6, 2040

    granted
  21. US 10703701

    Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

    PTC THERAPEUTICS, INC. · Granted Jul 7, 2020 · Expires Jul 2, 2040

    granted
  22. US 10688099

    Methods for modulating the amount of RNA transcripts

    PTC THERAPEUTICS, INC. · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted
  23. US 10675272

    Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease

    PTC THERAPEUTICS, INC. · Granted Jun 9, 2020 · Expires Jun 4, 2040

    granted
  24. US 10668171

    Methods for modulating RNA splicing

    PTC THERAPEUTICS, INC. · Granted Jun 2, 2020 · Expires May 28, 2040

    granted